New drug combo targets Hard-to-Treat HER2 cancers

NCT ID NCT05356741

Recruiting now Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called VIR-5818, alone or combined with the immunotherapy pembrolizumab, in people with advanced HER2-expressing cancers that have not responded to standard treatments. The study will first find the safest dose, then expand to see if the drug shrinks tumors. About 645 participants are expected to join across multiple cancer types.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VIR-5818 (an antibody-drug conjugate) and pembrolizumab (an immunotherapy)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced HER2-positive cancers that have stopped responding to other therapies.
What could go wrong: This is an early phase 1/2 trial, so the main goals are safety and dosing, not yet proving effectiveness. Side effects are unknown, and many early-stage cancer drugs do not advance to later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Investigational site number #100
RECRUITING

Melbourne, Victoria, 3000, Australia
Investigational site number #101
RECRUITING

Randwick, 2031, Australia
Investigational site number #150
RECRUITING

Toulouse, 31059, France
Investigational site number #200
RECRUITING

Porto, 4200-072, Portugal
Investigational site number #250
RECRUITING

Pamplona, 31008, Spain
Investigational site number #251
RECRUITING

Barcelona, 08035, Spain
Investigational site number #252
RECRUITING

Madrid, 28050, Spain
Investigational site number #253
RECRUITING

Pozuelo de Alarcón, 28223, Spain
Investigational site number #254
RECRUITING

Madrid, 28027, Spain
Investigational site number #255
RECRUITING

Barcelona, 08023, Spain